Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 06-M-0102 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to learn more about autism and its subtypes. Autism is a developmental disorder in which children have problems with communication and social skills and display restricted interests and repetitive behaviors.
This study has several goals. One aim is to look at types of autism that are known, such as the regressive subtype, (where skills are lost). We will explore whether there is a unique change in immune functioning related to this subtype. Another aim is to serve as one of the sites that will pilot a larger natural history study, entitled Autism Phenome Project. The goal is to further understand autism by identifying other subtypes.
We will look at several types of medical issues that may be related to autism, including immunologic problems. Children will be followed over the course of several years. We aim to capture medical problems that may be related to autism as they develop, and study outcomes in areas such as behavior and language, in order to explore known and new subtypes of autism.
Normally developing children (aged 1) with autism (age 1, and developmental delays other than autism (age 1), may be eligible for this study.
Depending on each child's study group and age, participants may undergo the following tests and procedures:
Baseline Visit
Follow-Up Visits
Follow-up visits are scheduled at different intervals, depending on study group, age and aspect of the study the child is enrolled in. The visits include a short interview session with the child's caregiver and assessment of the child's development and behavior. Some of the assessment measures used during the baseline examination are repeated, including symptoms ratings, behavioral tests and a blood test. For some children, the final visit will include repeats of the medical procedures.
Objective:
The current investigation focuses on finding meaningful subtypes of autism. Our objectives include using comprehensive and longitudinal medical assessments and behavioral testing to find subgroups of children with autism with profiles that comprise distinct biological/behavioral phenotypes.
Specific goals include determining if there is a unique alteration in immune function among autistic children with a regressive clinical course, and identifying autism-specific sleep and electroenchelalogram (EEG) abnormalities, and other potential biomarkers.
Study Population:
We are conducting a longitudinal natural history study of 140 children with autism, 12 to 84 months of age at study entry. We also are following as many as 75 typically developing children, and 50 children with Developmental Delay to serve as age-/sex-matched controls.
Design:
Systematic prospective evaluations are being utilized to determine diagnostic and functional outcomes, and evaluate behavioral, medical and immunologic functioning. These evaluations include comprehensive medical history, behavioral assessment, physical and neurologic examination, polysomnography (PSG) and EEG, and blood work for laboratory assays. Baseline evaluations also included MRI and lumbar puncture (the latter was only subjects with autism). In any investigation of behavioral outcomes and potential biomarkers, repeated assessments are necessary to determine whether findings are due to state versus trait alterations. Thus, key elements of the assessments are repeated every 6 to 12 months, depending on the child s age.
Outcome Variables:
Measures of autism symptoms and severity, along with cognitive and adaptive behavior profiles, will be used as behavioral outcome variables.
Results of physical and neurological examinations, genetic testing, EEGs, polysomnograms, MRI scans and laboratory assays of blood and CSF will be tested for their utility as biomarkers of autism s core symptoms or identification of etiologically related subgroups of patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Behavioral profiles | 6 to 12 months | |
| Immune markers | 6 to 12 months | |
| Sleep/EEG findings | 6 to 12 months | |
| Neuroimaging findings | 6 to 12 months | |
| Other laboratory findings | 6 to 12 months | |
| Genetic abnormalities | 6 to 12 months |
Not provided
Not provided
INCLUSION CRITERIA:
There are 3 participant groups in this study.
AUT: Children are included if they meet DSM-IV criteria for autistic disorder, based on ADI-R and ADOS and clinical judgment. Those meeting research criteria for autism will be included.
Regression is defined as: Language loss: Loss of at least 3 spontaneously meaningful words (excluding mama or dada) used for at least a month, and lost for at least a month.AND/OR Nonverbal communication/social loss: Loss of more than one nonverbal communicative behavior (e.g. gestures, joint attention, eye contact, imagination, pretend play, sharing, showing, watching children, orienting to name, social smiling, social games, spontaneous imitation of actions, response to social overtures). Although there is overlap in the age period for regression specified in this protocol (regression between 15-30 months) and that described for childhood disintegrative disorder (CDD) (the DSM-IV criteria for indicate apparently normal development for the first 2 years after birth ), the criteria for CDD also indicate a diagnosis can only be made if symptoms are not better accounted for by another pervasive developmental disorder such as autism. Symptoms of CDD that separate it from autism include loss of acquired skills in areas such as motor skills and bowel or bladder control, while the focus of the current study is on regression in core symptoms of autism (i.e. socio-communicative skills). Thus, the currently protocol will include children with regression over 2 who meet criteria for autism, but not those who only meet criteria for CDD.
DD: Developmental scores (Performance Quotient and Verbal Quotient) greater than 1.5 standard deviations below mean on Mullen Scales of Early Learning
TYP: No diagnosis of developmental delay, and no first-degree relatives with a history of autism spectrum disorders.
EXCLUSION CRITERIA:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Susan E Swedo, M.D. | National Institute of Mental Health (NIMH) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland | 20892 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 8353169 | Background | Ahlsen G, Rosengren L, Belfrage M, Palm A, Haglid K, Hamberger A, Gillberg C. Glial fibrillary acidic protein in the cerebrospinal fluid of children with autism and other neuropsychiatric disorders. Biol Psychiatry. 1993 May 15;33(10):734-43. doi: 10.1016/0006-3223(93)90124-v. | |
| 15031638 | Background | Ashwood P, Anthony A, Pellicer AA, Torrente F, Walker-Smith JA, Wakefield AJ. Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology. J Clin Immunol. 2003 Nov;23(6):504-17. doi: 10.1023/b:joci.0000010427.05143.bb. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000067877 | Autism Spectrum Disorder |
| D012640 | Seizures |
| D065886 | Neurodevelopmental Disorders |
| D009422 | Nervous System Diseases |
| D002659 | Child Development Disorders, Pervasive |
| D001321 | Autistic Disorder |
| ID | Term |
|---|---|
| D001523 | Mental Disorders |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
| 15546805 | Background | Ashwood P, Van de Water J. Is autism an autoimmune disease? Autoimmun Rev. 2004 Nov;3(7-8):557-62. doi: 10.1016/j.autrev.2004.07.036. |
| 34518555 | Derived | Farmer CA, Thurm AE, Honnekeri B, Kim P, Swedo SE, Han JC. The contribution of platelets to peripheral BDNF elevation in children with autism spectrum disorder. Sci Rep. 2021 Sep 13;11(1):18158. doi: 10.1038/s41598-021-97367-4. |
| 34504056 | Derived | Tierney E, Remaley AT, Thurm A, Jager LR, Wassif CA, Kratz LE, Bailey-Wilson JE, Bukelis I, Sarphare G, Jung ES, Brand B, Noah KK, Porter FD. Sterol and lipid analyses identifies hypolipidemia and apolipoprotein disorders in autism associated with adaptive functioning deficits. Transl Psychiatry. 2021 Sep 9;11(1):471. doi: 10.1038/s41398-021-01580-8. |
| 30152888 | Derived | Oztan O, Garner JP, Partap S, Sherr EH, Hardan AY, Farmer C, Thurm A, Swedo SE, Parker KJ. Cerebrospinal fluid vasopressin and symptom severity in children with autism. Ann Neurol. 2018 Oct;84(4):611-615. doi: 10.1002/ana.25314. Epub 2018 Sep 26. |
| 28120370 | Derived | Manwaring SS, Mead DL, Swineford L, Thurm A. Modelling gesture use and early language development in autism spectrum disorder. Int J Lang Commun Disord. 2017 Sep;52(5):637-651. doi: 10.1111/1460-6984.12308. Epub 2017 Jan 24. |
| 28070266 | Derived | Pardo CA, Farmer CA, Thurm A, Shebl FM, Ilieva J, Kalra S, Swedo S. Serum and cerebrospinal fluid immune mediators in children with autistic disorder: a longitudinal study. Mol Autism. 2017 Jan 5;8:1. doi: 10.1186/s13229-016-0115-7. eCollection 2017. |
| 27178705 | Derived | Shoffner J, Trommer B, Thurm A, Farmer C, Langley WA 3rd, Soskey L, Rodriguez AN, D'Souza P, Spence SJ, Hyland K, Swedo SE. CSF concentrations of 5-methyltetrahydrofolate in a cohort of young children with autism. Neurology. 2016 Jun 14;86(24):2258-63. doi: 10.1212/WNL.0000000000002766. Epub 2016 May 13. |
| 27096572 | Derived | Thurm A, Himelstein D, D'Souza P, Rennert O, Jiang S, Olatunji D, Longo N, Pasquali M, Swedo S, Salomons GS, Carrillo N. Creatine Transporter Deficiency: Screening of Males with Neurodevelopmental Disorders and Neurocognitive Characterization of a Case. J Dev Behav Pediatr. 2016 May;37(4):322-6. doi: 10.1097/DBP.0000000000000299. |
| 27061356 | Derived | Smith E, Thurm A, Greenstein D, Farmer C, Swedo S, Giedd J, Raznahan A. Cortical thickness change in autism during early childhood. Hum Brain Mapp. 2016 Jul;37(7):2616-29. doi: 10.1002/hbm.23195. Epub 2016 Apr 7. |
| 26844269 | Derived | Buckley AW, Scott R, Tyler A, Mahoney JM, Thurm A, Farmer C, Swedo S, Burroughs SA, Holmes GL. State-Dependent Differences in Functional Connectivity in Young Children With Autism Spectrum Disorder. EBioMedicine. 2015 Nov 5;2(12):1905-15. doi: 10.1016/j.ebiom.2015.11.004. eCollection 2015 Dec. |
| 26231264 | Derived | Lane R, Kessler R, Buckley AW, Rodriguez A, Farmer C, Thurm A, Swedo S, Felt B. Evaluation of Periodic Limb Movements in Sleep and Iron Status in Children With Autism. Pediatr Neurol. 2015 Oct;53(4):343-9. doi: 10.1016/j.pediatrneurol.2015.06.014. Epub 2015 Jun 26. |
| 24961159 | Derived | Thurm A, Manwaring SS, Swineford L, Farmer C. Longitudinal study of symptom severity and language in minimally verbal children with autism. J Child Psychol Psychiatry. 2015 Jan;56(1):97-104. doi: 10.1111/jcpp.12285. Epub 2014 Jun 24. |
| 24042076 | Derived | Graf-Myles J, Farmer C, Thurm A, Royster C, Kahn P, Soskey L, Rothschild L, Swedo S. Dietary adequacy of children with autism compared with controls and the impact of restricted diet. J Dev Behav Pediatr. 2013 Sep;34(7):449-59. doi: 10.1097/DBP.0b013e3182a00d17. |
| 23868881 | Derived | Joseph L, Thurm A, Farmer C, Shumway S. Repetitive behavior and restricted interests in young children with autism: comparisons with controls and stability over 2 years. Autism Res. 2013 Dec;6(6):584-95. doi: 10.1002/aur.1316. Epub 2013 Jul 18. |